Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Summary

Zentalis Pharmaceuticals closed an underwritten public offering of 26.45 million shares at $3.50 per share, raising approximately $92.6 million in gross proceeds. The company is advancing azenosertib, an investigational WEE1 inhibitor, for biomarker-driven treatment of ovarian cancer.